Kruttika Bhat1, Paul Medina1, Ling He1, Le Zhang1, Mohammad Saki1, Angeliki Ioannidis1, Nhan T Nguyen1, Sirajbir S Sodhi1, David Sung1, Clara E Magyar2, Linda M Liau3,4, Harley I Kornblum5,4, Frank Pajonk1,4. 1. Department of Radiation Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California. 2. Translational Pathology Core Laboratory, Image Analysis/Virtual Microscopy, Department of Pathology and Laboratory Medicine, Los Angeles, California. 3. Department of Neurosurgery, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California. 4. Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California. 5. NPI-Semel Institute for Neuroscience and Human Behavior at UCLA, Los Angeles, California.
Abstract
BACKGROUND: Normal tissue toxicity is an inevitable consequence of primary or secondary brain tumor radiotherapy. Cranial irradiation commonly leads to neurocognitive deficits that manifest months or years after treatment. Mechanistically, radiation-induced loss of neural stem/progenitor cells, neuroinflammation, and demyelination are contributing factors that lead to progressive cognitive decline. METHODS: The effects of 1-[(4-nitrophenyl)sulfonyl]-4-phenylpiperazine (NSPP) on irradiated murine neurospheres, microglia cells, and patient-derived gliomaspheres were assessed by sphere-formation assays, flow cytometry, and interleukin (IL)-6 enzyme-linked immunosorbent assay. Activation of the hedgehog pathway was studied by quantitative reverse transcription PCR. The in vivo effects of NSPP were analyzed using flow cytometry, sphere-formation assays, immunohistochemistry, behavioral testing, and an intracranial mouse model of glioblastoma. RESULTS: We report that NSPP mitigates radiation-induced normal tissue toxicity in the brains of mice. NSPP treatment significantly increased the number of neural stem/progenitor cells after brain irradiation in female animals, and inhibited radiation-induced microglia activation and expression of the pro-inflammatory cytokine IL-6. Behavioral testing revealed that treatment with NSPP after radiotherapy was able to successfully mitigate radiation-induced decline in memory function of the brain. In mouse models of glioblastoma, NSPP showed no toxicity and did not interfere with the growth-delaying effects of radiation. CONCLUSIONS: We conclude that NSPP has the potential to mitigate cognitive decline in patients undergoing partial or whole brain irradiation without promoting tumor growth and that the use of this compound as a radiation mitigator of radiation late effects on the central nervous system warrants further investigation.
BACKGROUND: Normal tissue toxicity is an inevitable consequence of primary or secondary brain tumor radiotherapy. Cranial irradiation commonly leads to neurocognitive deficits that manifest months or years after treatment. Mechanistically, radiation-induced loss of neural stem/progenitor cells, neuroinflammation, and demyelination are contributing factors that lead to progressive cognitive decline. METHODS: The effects of 1-[(4-nitrophenyl)sulfonyl]-4-phenylpiperazine (NSPP) on irradiated murine neurospheres, microglia cells, and patient-derived gliomaspheres were assessed by sphere-formation assays, flow cytometry, and interleukin (IL)-6 enzyme-linked immunosorbent assay. Activation of the hedgehog pathway was studied by quantitative reverse transcription PCR. The in vivo effects of NSPP were analyzed using flow cytometry, sphere-formation assays, immunohistochemistry, behavioral testing, and an intracranial mouse model of glioblastoma. RESULTS: We report that NSPP mitigates radiation-induced normal tissue toxicity in the brains of mice. NSPP treatment significantly increased the number of neural stem/progenitor cells after brain irradiation in female animals, and inhibited radiation-induced microglia activation and expression of the pro-inflammatory cytokine IL-6. Behavioral testing revealed that treatment with NSPP after radiotherapy was able to successfully mitigate radiation-induced decline in memory function of the brain. In mouse models of glioblastoma, NSPP showed no toxicity and did not interfere with the growth-delaying effects of radiation. CONCLUSIONS: We conclude that NSPP has the potential to mitigate cognitive decline in patients undergoing partial or whole brain irradiation without promoting tumor growth and that the use of this compound as a radiation mitigator of radiation late effects on the central nervous system warrants further investigation.
Authors: Michelle L Monje; Hannes Vogel; Marilyn Masek; Keith L Ligon; Paul G Fisher; Theo D Palmer Journal: Ann Neurol Date: 2007-11 Impact factor: 10.422
Authors: Paul D Brown; Kurt Jaeckle; Karla V Ballman; Elana Farace; Jane H Cerhan; S Keith Anderson; Xiomara W Carrero; Fred G Barker; Richard Deming; Stuart H Burri; Cynthia Ménard; Caroline Chung; Volker W Stieber; Bruce E Pollock; Evanthia Galanis; Jan C Buckner; Anthony L Asher Journal: JAMA Date: 2016-07-26 Impact factor: 56.272
Authors: James K Chen; Jussi Taipale; Keith E Young; Tapan Maiti; Philip A Beachy Journal: Proc Natl Acad Sci U S A Date: 2002-10-21 Impact factor: 11.205
Authors: Chelsea C Pinnix; Joachim Yahalom; Lena Specht; Bouthaina Shbib Dabaja Journal: Int J Radiat Oncol Biol Phys Date: 2018-06-06 Impact factor: 7.038
Authors: Winnie Wan Yee Tso; Anthony Pak Yin Liu; Tatia Mei Chun Lee; Ka Leung Cheuk; Ming Kong Shing; Chung Wing Luk; Siu Cheung Ling; Dennis Tak Loi Ku; Kenneth Li; Ada Wing Yan Yung; Cheuk Wing Fung; Sophelia Hoi Shan Chan; Alvin Chi Chung Ho; Frederick Ka Wing Ho; Patrick Ip; Godfrey Chi Fung Chan Journal: J Neurooncol Date: 2018-11-20 Impact factor: 4.130
Authors: Cátia Monteiro; Lauritz Miarka; María Perea-García; Neibla Priego; Pedro García-Gómez; Laura Álvaro-Espinosa; Ana de Pablos-Aragoneses; Natalia Yebra; Diana Retana; Patricia Baena; Coral Fustero-Torre; Osvaldo Graña-Castro; Kevin Troulé; Eduardo Caleiras; Patricia Tezanos; Pablo Muela; Elisa Cintado; José Luis Trejo; Juan Manuel Sepúlveda; Pedro González-León; Luis Jiménez-Roldán; Luis Miguel Moreno; Olga Esteban; Ángel Pérez-Núñez; Aurelio Hernández-Lain; José Mazarico Gallego; Irene Ferrer; Rocío Suárez; Eva M Garrido-Martín; Luis Paz-Ares; Celine Dalmasso; Elizabeth Cohen-Jonathan Moyal; Aurore Siegfried; Aisling Hegarty; Stephen Keelan; Damir Varešlija; Leonie S Young; Malte Mohme; Yvonne Goy; Harriet Wikman; Jose Fernández-Alén; Guillermo Blasco; Lucía Alcázar; Clara Cabañuz; Sergei I Grivennikov; Andrada Ianus; Noam Shemesh; Claudia C Faria; Rebecca Lee; Paul Lorigan; Emilie Le Rhun; Michael Weller; Riccardo Soffietti; Luca Bertero; Umberto Ricardi; Joaquim Bosch-Barrera; Elia Sais; Eduard Teixidor; Alejandro Hernández-Martínez; Alfonso Calvo; Javier Aristu; Santiago M Martin; Alvaro Gonzalez; Omer Adler; Neta Erez; Manuel Valiente Journal: Nat Med Date: 2022-04-11 Impact factor: 87.241
Authors: Ewa D Micewicz; Robert D Damoiseaux; Gang Deng; Adrian Gomez; Keisuke S Iwamoto; Michael E Jung; Christine Nguyen; Andrew J Norris; Josephine A Ratikan; Piotr Ruchala; James W Sayre; Dörthe Schaue; Julian P Whitelegge; William H McBride Journal: Front Pharmacol Date: 2021-05-18 Impact factor: 5.810